AEMD - Aethlon Medical, Inc.
| Previous Close | 3.6000 |
| Open | 3.4300 |
| Bid | 0.0000 x 1000 |
| Ask | 0.0000 x 3000 |
| Day's Range | 3.1000 - 3.5700 |
| 52 Week Range | 3.0000 - 26.1000 |
| Volume | 14,184 |
| Avg. Volume | 23,078 |
| Market Cap | 4.727M |
| Beta (3Y Monthly) | 0.96 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.8800 |
| Earnings Date | Feb 10, 2020 - Feb 14, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.00 |
- PR Newswire
Aethlon Medical Announces Second Quarter Financial Results and Provides Corporate Update
SAN DIEGO , Nov. 1, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, ...
- PR Newswire
Aethlon Medical To Release Second Quarter Financial Results and Host Conference Call on November 1, 2019
SAN DIEGO, Oct. 29, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its second quarter fiscal year 2020, ended September 30, 2019, at 4:15pm Eastern time on Friday, November 1, 2019. Management will host a conference call on Friday, November 1, 2019 at 4:30pm Eastern time to review financial results and recent corporate developments. To listen to the call by phone, interested parties within the U.S. should call 1-844-836-8741 and International callers should call 1-412-317-5442.
- Zacks Small Cap Research
AEMD: IDE Approved. Hemopurifier U.S. Clinical Cancer Program On-Deck…
By Brian Marckx, CFA NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT When Aethlon Medical (NASDAQ:AEMD) reported fiscal Q1 2020 financial results in August, management noted that they anticipated imminent filing of an Investigational Device Exemption (IDE) seeking approval to initiate U.S.-based clinical studies for their Hemopurifier device in cancer patients. Not only did that filing
- PR Newswire
Aethlon Announces Reverse Stock Split
SAN DIEGO, Oct. 14, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD) ("Aethlon" or the "Company"), a therapeutic medical device and technology company focused on unmet needs in global health, announced today that at the annual meeting of stockholders of the Company, held October 14, 2019, its stockholders voted to approve a proposal authorizing the Board of Directors of the Company to effect a reverse stock split of Aethlon's outstanding common stock. Following the special meeting of stockholders, the Board of Directors approved a 1-for-15 reverse stock split.
- PR Newswire
Aethlon Medical Announces FDA Approval Of IDE For Oncology Indications
SAN DIEGO, Oct. 7, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic medical device and technology company focused on unmet needs in global health, announced today that the FDA has approved its Investigational Device Exemption (IDE) application to initiate an Early Feasibility Study (EFS) of the Company's proprietary Hemopurifier® in patients with head and neck cancer in combination with standard of care pembrolizumab (Keytruda).
- PR Newswire
Aethlon Medical Receives Extension from Nasdaq to Regain Compliance with Continued Listing Requirements
SAN DIEGO, Oct. 3, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health, announced today that on October 2, 2019, Nasdaq granted Aethlon Medical an extension of time to regain compliance with the exchange's continued listing requirement of a minimum $2.5 million of stockholders' equity. This extension is conditional upon Aethlon Medical completing a reverse stock split and trading at or above Nasdaq's minimum $1.00 bid price requirement for a period of ten consecutive trading days on or before October 29, 2019. The Company is requesting stockholder approval of the reverse stock split at its Annual Meeting of Stockholders to be held on October 14, 2019 in order to meet this requirement.
- Simply Wall St.
How Much Of Aethlon Medical, Inc. (NASDAQ:AEMD) Do Insiders Own?
If you want to know who really controls Aethlon Medical, Inc. (NASDAQ:AEMD), then you'll have to look at the makeup of...
- Market Exclusive
Market Morning: Prorogation Ruled Rogue, High Demand for Fed Repo, New Breast Cancer Tests
British High Court Rules Against Johnson Parliament Prorogation Apparently, proroguing Parliament was not Boris Johnson’s prerogative. The British high court ruled today that the Prime Minister acted unlawfully in suspending Parliament until October 14th, and that he misled the Queen in advising that Parliament should be suspended. Johnson is now facing calls to resign, which […]The post Market Morning: Prorogation Ruled Rogue, High Demand for Fed Repo, New Breast Cancer Tests appeared first on Market Exclusive.
- PR Newswire
Aethlon Announces Collaboration to Identify Exosomes Involved in Cancer Progression and Treatment Resistance
SAN DIEGO, Sept. 24, 2019 /PRNewswire/ -- EXOSOME SCIENCES, a subsidiary of Aethlon Medical, Inc. (AEMD), announced a research collaboration to identify and characterize exosomes derived from patients with solid tumors such as pancreas cancer, as well as from families with genetically high risk of developing cancer. These cancer-derived exosomes may serve as early markers for cancer diagnostics, cancer progression and treatment resistance. Exosome Sciences, Inc., a majority owned subsidiary of Aethlon Medical, Inc., is a diagnostic company focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disease progression.
- PR Newswire
Aethlon Medical Receives National Cancer Institute Contract Award
SAN DIEGO, Sept. 16, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health, announced today that the National Cancer Institute (NCI) has awarded the Company an SBIR Phase 2 contract for Topic 359, a solicitation entitled "Technologies for Differential Isolation of Exosomes and Oncosomes." This solicitation prioritized the advancement of technologies for isolating exosomes from biofluids for applications in oncology research and clinical care. Exosomes are nanoparticles that are abundantly released from cancer cells and carry the complement of a tumor's genetic and protein cargo, making them important targets for non-invasive liquid biopsies in cancer. Aethlon is actively developing assays in this area through its majority-owned subsidiary, Exosome Sciences, Inc. However, there remains a need for high-throughput and selective technologies which isolate exosomes from various bodily fluids that could be adopted in clinical workflows.
- PR Newswire
Aethlon Medical Announces First Quarter Financial Results and Provides Corporate Update
SAN DIEGO , Aug. 14, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, today reported financial results for its first ...
- PR Newswire
Aethlon Medical To Release First Quarter Financial Results and Host Conference Call on August 14, 2019
SAN DIEGO, Aug. 7, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health, today announced that it will issue financial results for its first quarter fiscal year 2020, ended June 30, 2019, at 4:15pm Eastern time on Wednesday, August 14, 2019. Management will host a conference call on Wednesday, August 14, 2019 at 4:30pm eastern time to review financial results and recent corporate developments. To listen to the call by phone, interested parties within the U.S. should call 1-844-836-8741 and International callers should call 1-412-317-5442.
- Zacks Small Cap Research
AEMD: SeaStar Collaboration Is Intriguing, More Evidence of Exosomes’ Role in Cancer Progression
Aethlon Medical (AEMD) reported financial results for their fiscal fourth quarter ending March 31, 2019 and provided a business update. Revenue of $80k was recorded in the quarter, representing the initial payment under AEMD’s ongoing NCI grant (The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from the Blood Circulation), which was awarded in September 2018 and will pay a total of $298.4k through ~August 2019. This revenue relates to a completed milestone, “to evaluate Hemopurifier-mediated capture of breast cancer exosomes”.
- PR Newswire
Aethlon Medical Announces Fiscal Year End Financial Results and Provides Corporate Update
SAN DIEGO , July 1, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, today reported financial results for its fiscal ...
- ACCESSWIRE
Aethlon Medical, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / July 1, 2019 / Aethlon Medical, Inc. (NASDAQ: AEMD ) will be discussing their earnings results in their 2019 Fourth Quarter Earnings to be held on July 1, 2019 at 4:30 PM Eastern ...
- PR Newswire
Aethlon Medical, Inc. and SeaStar Medical, Inc. Announce Strategic Joint Cross-Licensing Agreement
SAN DIEGO and CARDIFF, Calif., July 1, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD) and SeaStar Medical, Inc. today announced a cross-licensing agreement to jointly develop their respective medical devices to address the care and management of critically ill patients. Aethlon Medical is developing the Hemopurifier®, a first-in-class blood purification cartridge used to remove a range of different particles from the blood, including cancer promoting exosomes for the treatment of cancers with no adequate alternative therapy and viruses for the treatment of life-threatening viral diseases. SeaStar's platform of cartridges include the CLR 2.0 Hemofilter which is FDA 510K cleared for acute kidney injury (AKI), congestive heart failure (CHF) and pulmonary edema and is currently being marketed for organ preservation in the solid organ transplant market. Each company's cartridges are designed to fit onto standard, hospital ICU-based equipment, either independently or together, and the companies plan to jointly develop complete treatment solutions that will allow deployment into multiple inpatient and outpatient treatment settings in any clinical indication where combined use of the Hemopurifier and CPCs may improve or expand indications for use, including but not limited to infectious disease, oncology and organ preservation and transplant.
- PR Newswire
Aethlon Medical To Release Fiscal Year End Financial Results and Host Conference Call on July 1, 2019
SAN DIEGO, June 19, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health, today announced that it will issue financial results for fiscal year 2019, ended March 31, 2019, at 4:15pm Eastern time on Monday, July 1, 2019. Management will host a conference call on Monday, July 1, 2019 at 4:30pm eastern time to review financial results and recent corporate developments. To listen to the call by phone, interested parties within the U.S. should call 1-844-836-8741 and International callers should call 1-412-317-5442.
- PR Newswire
Aethlon Medical Announces Collaboration With Prostate On-Site Project (POP), Host Of The Jerry Colangelo Sports Legend Golf Classic, To Engage With Participants For CTE Studies
PHOENIX, May 13, 2019 /PRNewswire/ -- Aethlon Medical Inc. (AEMD) and its diagnostic subsidiary, Exosome Sciences, in collaboration with the Translational Genomics Research Institute (TGen) and the Prostate On-Site Project (POP), announced that Aethlon, TGen and POP will engage with participants for their studies of chronic traumatic encephalopathy (CTE) in living individuals during the 18th annual Jerry Colangelo Sports Legends Golf Classic in Phoenix. Study participants will include former athletes who may have experienced repeated head impacts, such as former NFL players, as well as controls, those who played sports such as baseball that usually do not have significant head impacts.
- PR Newswire
Aethlon Medical Releases Shareholder Update
SAN DIEGO, April 17, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), today released the following shareholder update authored by its CEO, Timothy C. Rodell, M.D. With Chuck and the board's support and advice, our team is now working on executing a plan to advance Aethlon's unique Hemopurifier through clinical trials and regulatory approvals, toward ultimate commercialization as quickly and efficiently as possible. This process should be accelerated by the FDA's designation of the Hemopurifier as a "Breakthrough Device" for both viral diseases and cancer.
- Simply Wall St.
How Financially Strong Is Aethlon Medical, Inc. (NASDAQ:AEMD)?
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Aethlon Medical, Inc. (NASDAQ:AEMD) is a small-cap stock with a market capitalization of US$16m. While investors primarily fo...
- PR Newswire
Aethlon Medical, Inc. Announces Appointment of Lisa M. Boswell as Director, Quality Systems and Regulatory Affairs
SAN DIEGO, March 7, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic medical device company focused on addressing critical unmet needs in global health, announces the appointment of Lisa M. Boswell, to the position of Director, Quality Systems and Regulatory Affairs. Ms. Boswell has over 15 years of experience in Quality Control, Quality Assurance and Regulatory Affairs in both the biopharmaceutical and medical device industries, most recently as Director, Quality Assurance and Regulatory Affairs at ZOLL Data Systems, Inc.
- Zacks Small Cap Research
AEMD: Eventual FDA Cancer Indication Is A Realistic Outcome
Aethlon (AEMD) reported financial results for their fiscal third quarter ending December 31st and provided a business update. While we had modeled an initial payment under their ongoing NCI grant (The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from the Blood Circulation), which was awarded in September and will pay a total of $298.4k through ~August 2019, initial revenue is now expected to be recognized in the current (i.e.
- PR Newswire
Aethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update
SAN DIEGO , Feb. 11, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, today reported financial results for the third ...
- PR Newswire
Aethlon Medical To Release Quarterly Financial Results and Host Conference Call on February 11, 2019
SAN DIEGO, Feb. 4, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health, today announced that it will issue financial results for the third quarter of fiscal year 2019, ended December 31, 2018, at 4:15 pm eastern time on Monday, February 11, 2019. Management will host a conference call on Monday, February 11, 2019 at 4:30 pm eastern time to review financial results and recent corporate developments. International callers should call 1-412-317-5442.
